Home » Newsletters » BioWorld Science

BioWorld Science

May 23, 2007

View Archived Issues

Chloroquine to be evaluated for the treatment of metabolic syndrome / News in Context

Anxiety treatment with tandospirone improves atopic dermatitis

New targeted topical cream treatment shows promise in preclinical models of psoriasis

New therapeutic agents for renal-urological disorders disclosed in recent patents

Novel agents for treating neurological disorders revealed in patent literature

Recent patents describe possible new treatment options for diabetes

Quest Group International acquires new oncology product candidates

Phase III program planned for bapineuzumab in Alzheimer's

FDA awards orphan drug status to Ardana's oral growth hormone secretagogue

CUV-1647 begins phase III study in polymorphic light eruption

Tripep prepares for phase I/II study of ChronVac-C

Early close for tibolone study in breast cancer

Helsinn supports safety of nimesulide

New study compares safety of drug-eluting stents

KineMed evaluates mechanism of action of colesevelam in type 2 diabetes

CytRx updates operational activities

Talabostat clinical program placed on hold

CMC Biopharmaceuticals to support development of MORAb-028

Domain antibody PN-0621 begins phase I trial

MyVax studied in follicular NHL in phase II trial

AD-923 successfully completes pharmacokinetic study

Antigenics offers summary of Q1 events

Faster and prolonged acid suppression with AGN-201904-Z, an omeprazole prodrug

Amoxicillin PULSYS NDA accepted for filing

Lybrel receives FDA approval

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 3, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
5-HT2R allosteric ligands attenuate cocaine use and seeking behavior
BioWorld Science
Serotonergic G-protein-coupled receptors (GPCRs), including the 5-HT2A receptor (5-HT2AR) and 5-HT2CR, are key regulators of cortical signaling pathways and...